TY - JOUR
T1 - African green monkeys avoid SIV disease progression by preventing intestinal dysfunction and maintaining mucosal barrier integrity
AU - Raehtz, Kevin D.
AU - Barrenäs, Fredrik
AU - Xu, Cuiling
AU - Busman-Sahay, Kathleen
AU - Valentine, Audrey
AU - Law, Lynn
AU - Ma, Dongzhu
AU - Policicchio, Benjamin B.
AU - Wijewardana, Viskam
AU - Brocca-Cofano, Egidio
AU - Trichel, Anita
AU - Gale, Michael
AU - Keele, Brandon F.
AU - Estes, Jacob D.
AU - Apetrei, Cristian
AU - Pandrea, Ivona
N1 - Funding Information:
This work was funded by grants from the National Institutes of Health (NIH)/National Center for Research Resources/National Institute of Diabetes and Digestive and Kidney Diseases/ National Heart, Lung and Blood Institute/National Institute of Allergy and Infectious Diseases (NIAID): R01 RR025781 (CA/IP), R01DK113919 (IP/CA), R01DK119936 (CA), RO1 HL117715 (IP), R01 AI119346 (CA), R01 HL123096 (IP); base grants to the Oregon National Primate Research Center (ONPRC): P51OD011092 (JDE) and Washington National Primate Research Center (WNPRC): P51OD010425 (MG); NIAID/OD Contract HHSN272201800008C (MG); the Reagent Resource Support Program for AIDS Vaccine Development, Quality Biological, Gaithersburg, Maryland (DAIDS Contract N01-A30018) (MG); the WNPRC SVEU contract N01-AI-60006 (MG); and NCI/NIH contract HHSN261200800001E (BFK). Significant parts of this study were supported by start-up funds from the School of Medicine of the University of Pittsburgh. KDR and BBP were supported in part by the NIAID Pitt AIDS Research Training grant (T32 AI065380). Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
PY - 2020
Y1 - 2020
N2 - Unlike HIV infection, SIV infection is generally nonpathogenic in natural hosts, such as African green monkeys (AGMs), despite life-long high viral replication. Lack of disease progression was reportedly based on the ability of SIV-infected AGMs to prevent gut dysfunction, avoiding microbial translocation and the associated systemic immune activation and chronic inflammation. Yet, the maintenance of gut integrity has never been documented, and the mechanism(s) by which gut integrity is preserved are unknown. We sought to investigate the early events of SIV infection in AGMs, specifically examining the impact of SIVsab infection on the gut mucosa. Twenty-nine adult male AGMs were intrarectally infected with SIVsab92018 and serially sacrificed at well-defined stages of SIV infection, preramp-up (1-3 days post-infection (dpi)), ramp-up (4-6 dpi), peak viremia (9-12 dpi), and early chronic SIV infection (46-55 dpi), to assess the levels of immune activation, apoptosis, epithelial damage and microbial translocation in the GI tract and peripheral lymph nodes. Tissue viral loads, plasma cytokines and plasma markers of gut dysfunction were also measured throughout the course of early infection. While a strong, but transient, interferon-based inflammatory response was observed, the levels of plasma markers linked to enteropathy did not increase. Accordingly, no significant increases in apoptosis of either mucosal enterocytes or lymphocytes, and no damage to the mucosal epithelium were documented during early SIVsab infection of AGMs. These findings were supported by RNAseq of the gut tissue, which found no significant alterations in gene expression that would indicate microbial translocation. Thus, for the first time, we confirmed that gut epithelial integrity is preserved, with no evidence of microbial translocation, in AGMs throughout early SIVsab infection. This might protect AGMs from developing intestinal dysfunction and the subsequent chronic inflammation that drives both HIV disease progression and HIV-associated comorbidities.
AB - Unlike HIV infection, SIV infection is generally nonpathogenic in natural hosts, such as African green monkeys (AGMs), despite life-long high viral replication. Lack of disease progression was reportedly based on the ability of SIV-infected AGMs to prevent gut dysfunction, avoiding microbial translocation and the associated systemic immune activation and chronic inflammation. Yet, the maintenance of gut integrity has never been documented, and the mechanism(s) by which gut integrity is preserved are unknown. We sought to investigate the early events of SIV infection in AGMs, specifically examining the impact of SIVsab infection on the gut mucosa. Twenty-nine adult male AGMs were intrarectally infected with SIVsab92018 and serially sacrificed at well-defined stages of SIV infection, preramp-up (1-3 days post-infection (dpi)), ramp-up (4-6 dpi), peak viremia (9-12 dpi), and early chronic SIV infection (46-55 dpi), to assess the levels of immune activation, apoptosis, epithelial damage and microbial translocation in the GI tract and peripheral lymph nodes. Tissue viral loads, plasma cytokines and plasma markers of gut dysfunction were also measured throughout the course of early infection. While a strong, but transient, interferon-based inflammatory response was observed, the levels of plasma markers linked to enteropathy did not increase. Accordingly, no significant increases in apoptosis of either mucosal enterocytes or lymphocytes, and no damage to the mucosal epithelium were documented during early SIVsab infection of AGMs. These findings were supported by RNAseq of the gut tissue, which found no significant alterations in gene expression that would indicate microbial translocation. Thus, for the first time, we confirmed that gut epithelial integrity is preserved, with no evidence of microbial translocation, in AGMs throughout early SIVsab infection. This might protect AGMs from developing intestinal dysfunction and the subsequent chronic inflammation that drives both HIV disease progression and HIV-associated comorbidities.
UR - http://www.scopus.com/inward/record.url?scp=85082095401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082095401&partnerID=8YFLogxK
U2 - 10.1371/journal.ppat.1008333
DO - 10.1371/journal.ppat.1008333
M3 - Article
C2 - 32119719
AN - SCOPUS:85082095401
SN - 1553-7366
VL - 16
JO - PLoS Pathogens
JF - PLoS Pathogens
IS - 3
M1 - e1008333
ER -